AR114110A1 - Anticuerpo anti-trka - Google Patents
Anticuerpo anti-trkaInfo
- Publication number
- AR114110A1 AR114110A1 ARP190100363A ARP190100363A AR114110A1 AR 114110 A1 AR114110 A1 AR 114110A1 AR P190100363 A ARP190100363 A AR P190100363A AR P190100363 A ARP190100363 A AR P190100363A AR 114110 A1 AR114110 A1 AR 114110A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- antibodies
- trka antibody
- trka
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Anticuerpos contra el receptor tropomiosina quinasa (TrkA), composiciones que incluyen tales anticuerpos y métodos de uso de tales anticuerpos para el tratamiento del dolor, que incluye el dolor posquirúrgico, el dolor por artritis reumatoide, el dolor neuropático y el dolor por osteoartritis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862636207P | 2018-02-28 | 2018-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114110A1 true AR114110A1 (es) | 2020-07-22 |
Family
ID=65686081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190100363A AR114110A1 (es) | 2018-02-28 | 2019-02-14 | Anticuerpo anti-trka |
Country Status (7)
Country | Link |
---|---|
US (1) | US10618974B2 (es) |
EP (1) | EP3759138A1 (es) |
JP (1) | JP7017641B2 (es) |
CN (1) | CN111788230B (es) |
AR (1) | AR114110A1 (es) |
TW (1) | TWI702233B (es) |
WO (1) | WO2019168730A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202210467A (zh) | 2020-05-28 | 2022-03-16 | 美商美國禮來大藥廠 | TrkA抑制劑 |
CN112961244B (zh) * | 2021-02-28 | 2023-08-29 | 熙源安健医药(上海)有限公司 | 抗TrkA抗体或其抗原结合片段、其制备方法和应用 |
WO2023125490A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Suzhou) Limited | TrkA ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0471205A1 (en) | 1990-08-15 | 1992-02-19 | E.R. SQUIBB & SONS, INC. | Monoclonal antibodies which bind TRK proto-oncogene protein |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US20040058416A1 (en) | 1994-03-18 | 2004-03-25 | Presta Leonard G. | Human trk receptors and neurotrophic factor inhibitors |
NZ501161A (en) | 1994-03-18 | 2001-03-30 | Genentech Inc | Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor. |
GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
US20020169154A1 (en) | 2001-04-04 | 2002-11-14 | Cephalon, Inc. | Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents |
CN102746399B (zh) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
WO2005019266A2 (en) | 2003-07-15 | 2005-03-03 | Amgen Inc. | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
US20060058250A1 (en) | 2004-09-10 | 2006-03-16 | Cephalon, Inc. | Methods of treating proliferative skin diseases using carbazole derivatives |
US20060275797A1 (en) | 2005-03-21 | 2006-12-07 | Alcon Manufacturing, Ltd. | Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders |
AU2014277649A1 (en) | 2005-06-07 | 2015-01-22 | Abbott Research B.V | Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
EP1933714B1 (en) | 2005-09-21 | 2020-03-18 | The Regents of The University of California | Systems and compositions for local imaging and treatment of pain |
ITRM20060367A1 (it) | 2006-07-13 | 2008-01-14 | Lay Line Genomics Spa | Muteine del hngf usi terapeutici e composizioni farmaceutiche |
WO2008013782A2 (en) | 2006-07-24 | 2008-01-31 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists |
US8144893B2 (en) | 2007-07-26 | 2012-03-27 | Sherman Kenneth N | Mobile microphone |
WO2009036068A2 (en) | 2007-09-14 | 2009-03-19 | Emory University | Gambogic amine, a selective trka agonist with neuroprotective activity |
KR101782857B1 (ko) | 2008-02-04 | 2017-09-28 | 레이 라인 지노믹스 에스.피.에이. | 항―trka 항체 및 이의 유도체 |
WO2012009640A2 (en) | 2010-07-16 | 2012-01-19 | The Ohio State University | B cell depletion for central nervous system injuries and methods and uses thereof |
US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
JP2012201621A (ja) | 2011-03-24 | 2012-10-22 | Univ Of Fukui | TrkAを阻害するペプチド化合物及びその用途 |
WO2013026021A2 (en) | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
EA201492163A1 (ru) | 2012-06-08 | 2015-08-31 | Гленмарк Фармасьютикалс С.А. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ |
EP2674439B1 (en) * | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
WO2014071358A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
FR3025717A1 (fr) | 2014-09-16 | 2016-03-18 | Univ Lille Sciences Tech | Utilisation conjointe d'un inhibiteur de trka et d'un inhibiteur de epha2 pour une utilisation dans le traitement de cancers |
GB201418713D0 (en) | 2014-10-21 | 2014-12-03 | Kymab Ltd | Bindings Proteins |
US9517238B2 (en) | 2014-11-07 | 2016-12-13 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammation through inhibition of NTRK1 |
MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
AU2015364557C1 (en) | 2014-12-18 | 2021-11-18 | Genzyme Corporation | Pharmaceutical formulations of tropomyosin related kinase (Trk) inhibitors |
WO2016146730A1 (en) | 2015-03-19 | 2016-09-22 | Neuheart S.R.L. | PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY |
US20170362327A1 (en) | 2015-04-24 | 2017-12-21 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain |
AU2016370846B2 (en) | 2015-12-18 | 2022-08-25 | Ignyta, Inc. | Combinations for the treatment of cancer |
EP3506928A2 (en) | 2016-09-02 | 2019-07-10 | European Molecular Biology Laboratory | Irradiation treatment of neurological sensations by photoablation |
-
2019
- 2019-02-14 AR ARP190100363A patent/AR114110A1/es unknown
- 2019-02-15 TW TW108105098A patent/TWI702233B/zh active
- 2019-02-21 US US16/281,227 patent/US10618974B2/en active Active
- 2019-02-21 EP EP19709296.8A patent/EP3759138A1/en active Pending
- 2019-02-21 JP JP2020544503A patent/JP7017641B2/ja active Active
- 2019-02-21 WO PCT/US2019/018869 patent/WO2019168730A1/en unknown
- 2019-02-21 CN CN201980016047.8A patent/CN111788230B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111788230A (zh) | 2020-10-16 |
JP2021514960A (ja) | 2021-06-17 |
TWI702233B (zh) | 2020-08-21 |
JP7017641B2 (ja) | 2022-02-08 |
US20190263932A1 (en) | 2019-08-29 |
CN111788230B (zh) | 2023-11-03 |
WO2019168730A1 (en) | 2019-09-06 |
EP3759138A1 (en) | 2021-01-06 |
US10618974B2 (en) | 2020-04-14 |
TW201945400A (zh) | 2019-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114110A1 (es) | Anticuerpo anti-trka | |
MX2023006482A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
PH12018500766A1 (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
CL2018003515A1 (es) | Anticuerpos anti-gitr y sus usos. | |
CL2020000938A1 (es) | Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744) | |
CL2022001271A1 (es) | Agonista del receptor glp-1 y uso de este | |
PH12019502411A1 (en) | Cells expressing chimeric activitaing receptors and chimeric stimulating receptors and uses thereof | |
CO2021008696A2 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
PE20190622A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
CL2019003270A1 (es) | Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. | |
EA201791127A1 (ru) | Антитела, содержащие модифицированные константные участки тяжелой цепи | |
PE20180330A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso | |
CL2016002547A1 (es) | Anticuerpos contra her2 biespecíficos | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
AR061568A1 (es) | Compuestos | |
CL2016001028A1 (es) | Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh. | |
MX2020013017A (es) | Materiales y metodos para tratar cancer. | |
CL2008003802A1 (es) | Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple. | |
BR112018067851A2 (pt) | composições e métodos para o tratamento de artrite reumatoide | |
PE20170943A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
EA201691691A1 (ru) | Белки слияния tatk-cdkl5, их композиции, составы и применение |